Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Assets (2016 - 2025)

Organogenesis Holdings (ORGO) has 10 years of Assets data on record, last reported at $598.7 million in Q4 2025.

  • For Q4 2025, Assets rose 20.25% year-over-year to $598.7 million; the TTM value through Dec 2025 reached $598.7 million, up 20.25%, while the annual FY2025 figure was $598.7 million, 20.25% up from the prior year.
  • Assets reached $598.7 million in Q4 2025 per ORGO's latest filing, up from $509.8 million in the prior quarter.
  • Across five years, Assets topped out at $598.7 million in Q4 2025 and bottomed at $319.2 million in Q1 2021.
  • Average Assets over 5 years is $449.5 million, with a median of $453.3 million recorded in 2022.
  • Peak YoY movement for Assets: skyrocketed 64.24% in 2021, then decreased 3.53% in 2024.
  • A 5-year view of Assets shows it stood at $443.3 million in 2021, then increased by 1.38% to $449.4 million in 2022, then increased by 2.37% to $460.0 million in 2023, then grew by 8.23% to $497.9 million in 2024, then increased by 20.25% to $598.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Assets were $598.7 million in Q4 2025, $509.8 million in Q3 2025, and $461.1 million in Q2 2025.